ZA201501494B - Sirna and their use in methods and compositions for the treatment and/or prevention of eye conditions - Google Patents

Sirna and their use in methods and compositions for the treatment and/or prevention of eye conditions

Info

Publication number
ZA201501494B
ZA201501494B ZA2015/01494A ZA201501494A ZA201501494B ZA 201501494 B ZA201501494 B ZA 201501494B ZA 2015/01494 A ZA2015/01494 A ZA 2015/01494A ZA 201501494 A ZA201501494 A ZA 201501494A ZA 201501494 B ZA201501494 B ZA 201501494B
Authority
ZA
South Africa
Prior art keywords
sirna
prevention
compositions
treatment
methods
Prior art date
Application number
ZA2015/01494A
Other languages
English (en)
Inventor
Fajardo Victoria Gonzalez
Palomar Veronica Ruz
Anton Ana Isabel Jimenez
Original Assignee
Sylentis Sau
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sylentis Sau filed Critical Sylentis Sau
Publication of ZA201501494B publication Critical patent/ZA201501494B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/04Artificial tears; Irrigation solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering nucleic acids [NA]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/3212'-O-R Modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
ZA2015/01494A 2012-09-05 2015-03-04 Sirna and their use in methods and compositions for the treatment and/or prevention of eye conditions ZA201501494B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1215857.2A GB201215857D0 (en) 2012-09-05 2012-09-05 siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
PCT/EP2013/068245 WO2014037377A1 (en) 2012-09-05 2013-09-04 Sirna and their use in methods and compositions for the treatment and/or prevention of eye conditions

Publications (1)

Publication Number Publication Date
ZA201501494B true ZA201501494B (en) 2016-01-27

Family

ID=47136985

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2015/01494A ZA201501494B (en) 2012-09-05 2015-03-04 Sirna and their use in methods and compositions for the treatment and/or prevention of eye conditions

Country Status (29)

Country Link
US (1) US9808479B2 (enExample)
EP (1) EP2893019B1 (enExample)
JP (2) JP2015529210A (enExample)
KR (1) KR102136539B1 (enExample)
CN (2) CN104640988A (enExample)
AU (1) AU2013311781B2 (enExample)
BR (1) BR112015004469B8 (enExample)
CA (1) CA2883040C (enExample)
CL (1) CL2015000537A1 (enExample)
CY (1) CY1121000T1 (enExample)
DK (1) DK2893019T3 (enExample)
EC (1) ECSP15009391A (enExample)
ES (1) ES2685346T3 (enExample)
GB (1) GB201215857D0 (enExample)
HR (1) HRP20181079T1 (enExample)
HU (1) HUE040096T2 (enExample)
IL (1) IL237389B (enExample)
IN (1) IN2015DN02501A (enExample)
LT (1) LT2893019T (enExample)
MX (1) MX362854B (enExample)
PE (1) PE20150619A1 (enExample)
PL (1) PL2893019T3 (enExample)
PT (1) PT2893019T (enExample)
RS (1) RS57620B1 (enExample)
RU (1) RU2663100C2 (enExample)
SG (1) SG11201501386TA (enExample)
SI (1) SI2893019T1 (enExample)
WO (1) WO2014037377A1 (enExample)
ZA (1) ZA201501494B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3901263A1 (en) 2011-06-30 2021-10-27 Arrowhead Pharmaceuticals, Inc. Compositions and methods for inhibiting gene expression of hepatitis b virus
CN108271387B (zh) 2015-08-07 2023-06-27 箭头药业股份有限公司 乙型肝炎病毒感染的RNAi疗法
JOP20170161A1 (ar) 2016-08-04 2019-01-30 Arrowhead Pharmaceuticals Inc عوامل RNAi للعدوى بفيروس التهاب الكبد ب
JP6994061B2 (ja) 2019-02-15 2022-01-14 ノバルティス アーゲー 4-(7-ヒドロキシ-2-イソプロピル-4-オキソ-4h-キナゾリン-3-イル)-ベンゾニトリルの製剤
SG11202107260VA (en) 2019-02-15 2021-08-30 Novartis Ag Methods for treating ocular surface pain
HUE072085T2 (hu) * 2019-10-04 2025-10-28 Senju Pharma Co Gyógyszerészeti készítmény, mely heterocikliden-acetamid-származékot tartalmaz és amely a száraz szem kezelésére szolgál

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4343794A (en) 1980-05-06 1982-08-10 Mt. Sinai Method of reducing intraocular pressure with salts of vanadic acid
US4652586A (en) 1980-11-07 1987-03-24 The General Hospital Corporation Selective beta-2 adrenergic antagonists for the treatment of glaucoma
US4617299A (en) 1983-12-19 1986-10-14 Knepper Paul A Method for the prevention of ocular hypertension, treatment of glaucoma and treatment of ocular hypertension
US5242943A (en) 1984-03-28 1993-09-07 William J. Louis 3-aminopropoxyphenyl derivatives, their preparation and pharmaceutical compositions containing them
US4812448A (en) 1984-10-22 1989-03-14 Knepper Paul A Method for the prevention of ocular hypertension, treatment of glaucoma and treatment of ocular hypertension
US4757089A (en) 1985-06-14 1988-07-12 Massachusetts Eye And Ear Infirmary Increasing aqueous humor outflow
US5075323A (en) 1988-08-24 1991-12-24 Aktiebolaget Hassle Compounds including omeprazole in the treatment of glaucoma
US5260059A (en) 1989-04-14 1993-11-09 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon Health Sciences University Treatment of open-angle glaucoma by modulation matrix metalloproteinases and their inhibitor
US6372249B1 (en) 1991-12-16 2002-04-16 Baylor College Of Medicine Senscent cell-derived inhibitors of DNA synthesis
US5464866A (en) 1992-08-17 1995-11-07 Alcon Laboratories, Inc. Substituted hydrindanes for the treatment of angiogenesis-dependent diseases
US5545626A (en) 1994-01-19 1996-08-13 The Trustees Of Columbia University In The City Of New York Method of treating glaucoma with oligonucleotides
US5585401A (en) 1994-12-09 1996-12-17 The Reents Of The University Of California Method for enhancing outflow of aqueous humor in treatment of glaucoma
US20020055536A1 (en) 1996-09-26 2002-05-09 Dewitte Robert S. System and method for structure-based drug design that includes accurate prediction of binding free energy
US6489307B1 (en) 1998-09-14 2002-12-03 University Of Florida Antisense compositions targeted to β1-adrenoceptor-specific mRNA and methods of use
EP2314700A1 (en) 1999-01-28 2011-04-27 Medical College of Georgia Research Institute, Inc Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA
US6365576B1 (en) 1999-06-24 2002-04-02 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Method for inhibiting herpes infection
ES2215494T5 (es) 2000-12-01 2017-12-28 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Moléculas de RNA pequeñas que median la interferencia de RNA
US20020165158A1 (en) 2001-03-27 2002-11-07 King George L. Methods of modulating angiogenesis
US20070049543A1 (en) 2001-05-18 2007-03-01 Sirna Therapeutics, Inc. RNA interference mediated inhibition of 11 beta-hydroxysteroid dehydrogenase-1 (11 beta-HSD-1) gene expression using short interfering nucleic acid siNA
US20040209832A1 (en) 2001-11-30 2004-10-21 Mcswiggen James RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20050148530A1 (en) 2002-02-20 2005-07-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
EP1587574A4 (en) 2001-12-21 2009-03-18 Rhode Island Hospital SELECTIVE 11b-HSD HEMMER AND METHOD OF USE THEREOF
US7294504B1 (en) 2001-12-27 2007-11-13 Allele Biotechnology & Pharmaceuticals, Inc. Methods and compositions for DNA mediated gene silencing
GB2406568B (en) 2002-02-20 2005-09-28 Sirna Therapeutics Inc RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
AU2003207708A1 (en) 2002-02-20 2003-09-09 Sirna Therapeutics, Inc. Rna interference mediated inhibition of map kinase genes
ES2397060T3 (es) 2002-04-18 2013-03-04 Opko Pharmaceuticals, Llc Medios y métodos para la modulación específica de genes diana en el ojo
US20040115641A1 (en) 2002-12-11 2004-06-17 Isis Pharmaceuticals Inc. Modulation of ROCK 1 expression
EP1554386A2 (en) 2002-07-24 2005-07-20 Immusol Incorporated Single promoter system for making sirna expression cassettes and expression libraries using a polymerase primer hairpin linker
EP1534840A4 (en) 2002-07-24 2006-01-18 Immusol Inc NEW SIRNA GENIUS LIBRARIES AND METHOD FOR THEIR MANUFACTURE AND USE
DK2258847T3 (en) 2002-08-05 2017-06-26 Silence Therapeutics Gmbh Additional new forms of interfering RNA molecules
US20040029275A1 (en) 2002-08-10 2004-02-12 David Brown Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs
US20050020521A1 (en) 2002-09-25 2005-01-27 University Of Massachusetts In vivo gene silencing by chemically modified and stable siRNA
CA2504926C (en) 2002-11-01 2014-01-14 The Trustees Of The University Of Pennsylvania Compositions and methods for sirna inhibition of hif-1 alpha
DE10322662A1 (de) 2002-11-06 2004-10-07 Grünenthal GmbH Wirksame und stabile DNA-Enzyme
WO2006006948A2 (en) 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
EP2284266B1 (en) 2002-11-14 2013-11-06 Thermo Fisher Scientific Biosciences Inc. siRNA targeting tp53
US7250496B2 (en) 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
US20060257851A1 (en) 2002-11-26 2006-11-16 Itzhak Bentwich Bioinformatically detectable group of novel viral regulatory genes and uses thereof
US20040167090A1 (en) 2003-02-21 2004-08-26 Monahan Sean D. Covalent modification of RNA for in vitro and in vivo delivery
GB0307206D0 (en) 2003-03-28 2003-04-30 Axordia Ltd Hyperproliferation
US20040198640A1 (en) 2003-04-02 2004-10-07 Dharmacon, Inc. Stabilized polynucleotides for use in RNA interference
WO2004099372A2 (en) 2003-05-01 2004-11-18 University Of Florida Anti-scarring ribozymes and methods
US20040224405A1 (en) 2003-05-06 2004-11-11 Dharmacon Inc. siRNA induced systemic gene silencing in mammalian systems
US20060241072A1 (en) 2003-06-20 2006-10-26 Isis Pharmaceuticals, Inc. Oligomeric compounds for use in gene modulation
JP2007525482A (ja) 2003-10-07 2007-09-06 レノビス, インコーポレイテッド イオンチャネルリガンドとしてのアミド化合物およびその使用
WO2005045037A2 (en) 2003-10-23 2005-05-19 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF 5-ALPHA REDUCTASE AND ANDROGEN RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
KR20050039573A (ko) 2003-10-23 2005-04-29 주식회사 태평양 티오우레아계 유도체의 용해성과 생체이용률이 개선된약제학적 조성물
US20050208658A1 (en) 2003-11-21 2005-09-22 The University Of Maryland RNA interference mediated inhibition of 11beta hydroxysteriod dehydrogenase-1 (11beta HSD-1) gene expression
SG187381A1 (en) * 2003-12-03 2013-02-28 Coda Therapeutics Nz Ltd Antisense compounds targeted to connexins and methods of use thereof
US7544803B2 (en) 2004-01-23 2009-06-09 Amgen Inc. Vanilloid receptor ligands and their use in treatments
WO2005076998A2 (en) 2004-02-05 2005-08-25 Intradigm Corporation Rnai therapeutics for treatment of eye neovascularization diseases
GB0403600D0 (en) 2004-02-18 2004-03-24 Trinity College Dublin Methods and reagents for treating disease
EP1735009A4 (en) 2004-03-12 2011-03-30 Alnylam Pharmaceuticals Inc RNAI AGENTS TARGETING THE VASCULAR ENDOTHELIUM GROWTH FACTOR (VEGF)
KR101147147B1 (ko) 2004-04-01 2012-05-25 머크 샤프 앤드 돔 코포레이션 Rna 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
WO2005117938A2 (en) 2004-04-13 2005-12-15 Regents Of The University Of Minnesota Methods of treating ocular conditions
EP1768954A4 (en) 2004-06-24 2008-05-28 Incyte Corp 2-METHYLPROPANAMIDES AND THEIR USE AS PHARMACEUTICALS
EP1791567B1 (en) 2004-08-10 2015-07-29 Alnylam Pharmaceuticals Inc. Chemically modified oligonucleotides
US8030284B2 (en) 2004-08-23 2011-10-04 Sylentis S.A.U. Treatment of eye disorders characterized by an elevated intraocular pressure by siRNAs
TW200639252A (en) 2005-02-01 2006-11-16 Alcon Inc RNAi-mediated inhibition of ocular hypertension targets
CA2598234A1 (en) 2005-03-11 2006-09-21 Alcon, Inc. Rnai-mediated inhibition of frizzled related protein-1 for treatment of glaucoma
GB0521351D0 (en) 2005-10-20 2005-11-30 Genomica Sau Modulation of TRPV expression levels
MX2009001896A (es) * 2006-08-24 2009-04-17 Alcon Res Ltd Inhibicion medida por arn-i de gremlin para el tratamiento de condiciones relacionadas con iop.
US20110160279A1 (en) 2007-08-13 2011-06-30 Board Of Trustees Of Southern Illinois University METHODS FOR TREATMENT AND PREVENTION OF OTOTOXICITY BY siRNA
TW200927192A (en) 2007-11-19 2009-07-01 Alcon Res Ltd Use of TRPV1 receptor antagonists for treating dry eye and ocular pain
CN201337650Y (zh) * 2009-01-06 2009-11-04 河北科技大学 一次性药用单剂量液体容器
EP2390327A1 (en) 2010-05-27 2011-11-30 Sylentis S.A. siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions

Also Published As

Publication number Publication date
CA2883040C (en) 2023-01-17
CN108354944A (zh) 2018-08-03
PT2893019T (pt) 2018-10-19
ECSP15009391A (es) 2015-12-31
DK2893019T3 (en) 2018-09-03
CL2015000537A1 (es) 2015-07-10
IL237389B (en) 2019-01-31
MX362854B (es) 2019-02-20
RU2015112121A (ru) 2016-10-27
HK1212377A1 (en) 2016-06-10
US9808479B2 (en) 2017-11-07
JP2015529210A (ja) 2015-10-05
IN2015DN02501A (enExample) 2015-09-11
JP6742362B2 (ja) 2020-08-19
GB201215857D0 (en) 2012-10-24
WO2014037377A1 (en) 2014-03-13
KR102136539B1 (ko) 2020-07-23
BR112015004469A2 (pt) 2017-08-08
SI2893019T1 (sl) 2018-09-28
ES2685346T3 (es) 2018-10-08
US20150224131A1 (en) 2015-08-13
RU2663100C2 (ru) 2018-08-01
BR112015004469B8 (pt) 2022-12-06
SG11201501386TA (en) 2015-03-30
AU2013311781A1 (en) 2015-03-12
AU2013311781B2 (en) 2018-10-18
EP2893019A1 (en) 2015-07-15
KR20150047513A (ko) 2015-05-04
LT2893019T (lt) 2018-08-10
CA2883040A1 (en) 2014-03-13
PL2893019T3 (pl) 2018-12-31
EP2893019B1 (en) 2018-05-30
JP2018138596A (ja) 2018-09-06
BR112015004469B1 (pt) 2022-11-16
CN104640988A (zh) 2015-05-20
IL237389A0 (en) 2015-04-30
HUE040096T2 (hu) 2019-02-28
MX2015002802A (es) 2015-05-15
HRP20181079T1 (hr) 2018-09-07
CY1121000T1 (el) 2019-12-11
PE20150619A1 (es) 2015-05-11
RS57620B1 (sr) 2018-11-30

Similar Documents

Publication Publication Date Title
EP2817018A4 (en) METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING OPHTHALMIC CONDITIONS
ZA201402615B (en) Prevention and treatment of ocular conditions
EP2831001A4 (en) COMPOSITION FOR THE TREATMENT OF WATER AND METHOD FOR USE
IL237528A0 (en) Methods for preventing and treating preeclampsia
GB201217296D0 (en) Method of treatment and/or prevention
ZA201408055B (en) Compositions and methods for the treatment of local pain
ZA201408056B (en) Compositions and methods for the treatment of mucositis
PT2576782T (pt) Arnsi e utilização dos mesmos em métodos e composições para o tratamento e/ou prevenção de condições oculares
EP2869819A4 (en) COMPOSITIONS, METHODS AND / OR DEVICES FOR THE PREVENTION AND / OR TREATMENT OF OCULAR DROUGHT DISORDERS
PL2854910T3 (pl) Poziomy ceramidu w leczeniu i zapobieganiu infekcjom
ZA201501494B (en) Sirna and their use in methods and compositions for the treatment and/or prevention of eye conditions
IL245123A0 (en) Short interfering RNA and its use in methods and preparations for preventing the expression of the orai1 gene
ZA201307058B (en) Use of polyaminoisoprenyl derrivatives in antobiotic or antisertic treatment
ZA201502181B (en) Sirna and their use in methods and compositions for the treatment and/or prevention of eye conditions
IL222482A0 (en) Methods and compositions for the treatment of fluid accumulation in and/or under the retina
ZA201408058B (en) Compositions and methods for the treatment of epilepsy
SG11201500838UA (en) Eprotirome for use in the prevention and/or treatment of hair disorders and compositions thereof
PL2862576T3 (pl) Drobnoustroje i zawierające je kompozycje do stosowania do leczenia lub profilaktyki zapalenia sutka
IL243237A0 (en) Methods and preparations for the treatment of fluid accumulation in and/or under the retina
AU2012902937A0 (en) Composition for prevention and treatment of eye disorder
ZA201501068B (en) Methods for prevention and treatment of preeclampsia